CTMX
CytomX Therapeutics, Inc.
Price Chart
Latest Quote
$2.95
-0.01 (-0.34%)
Current Price
| Previous Close | $2.96 |
| Open | $3.00 |
| Day High | $3.07 |
| Day Low | $2.90 |
| Volume | 6,748,962 |
Stock Information
| Shares Outstanding | 217.70M |
| Total Debt | $2.86M |
| Cash Equivalents | $346.71M |
| Revenue | $35.54M |
| Net Income | $-62.14M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $642.22M |
| EPS (TTM) | $-0.52 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $298.37M |
| Sales | $35.54M |
| Income | $-62.14M |
| Book/sh | $1.47 |
| Cash/sh | $1.59 |
| Employees | 69 |
Financial Ratios
| Quick Ratio | 10.21 |
| Current Ratio | 10.38 |
| Debt/Eq | 0.89 |
Returns & Margins
| ROA | -16.89% |
| ROE | -34.28% |
| Gross Margin | 100.00% |
| Operating Margin | -191.77% |
| Profit Margin | -166.40% |
Ownership
| Insider Ownership | 0.56% |
| Institutional Ownership | 96.33% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.07 |
| P/S | 18.07 |
| P/B | 2.01 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $12.50 |
Technical Indicators
| SMA20 | $3.25 |
| SMA50 | $3.82 |
| SMA200 | $4.06 |
| RSI | 22.22 |
| ATR | 0.1758 |
| Shares Float | 186.26M |
| Short Float | 14.97% |
| Short Ratio | 9.27 |
| Volatility | 2.09 |
| Rel Volume | 2.40 |
Performance History
| Week | -1.01% |
| Month | -18.96% |
| Quarter | -38.28% |
| 6 Months | -30.59% |
| YTD | -30.59% |
| Year | +23.95% |
| 3 Years | +76.65% |
| 5 Years | -58.80% |
| 10 Years | -68.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.95 | 9,732,400 |
| 2026-06-17 | $2.96 | 5,519,800 |
| 2026-06-16 | $2.93 | 10,574,100 |
| 2026-06-15 | $3.04 | 2,921,200 |
| 2026-06-12 | $3.01 | 2,049,900 |
| 2026-06-11 | $2.98 | 2,271,700 |
| 2026-06-10 | $2.91 | 2,015,800 |
| 2026-06-09 | $2.98 | 4,596,000 |
| 2026-06-08 | $2.94 | 3,643,300 |
| 2026-06-05 | $3.00 | 3,419,400 |
| 2026-06-04 | $3.18 | 3,240,400 |
| 2026-06-03 | $3.22 | 3,543,300 |
| 2026-06-02 | $3.16 | 4,927,800 |
| 2026-06-01 | $3.45 | 6,708,400 |
| 2026-05-29 | $3.60 | 2,626,100 |
| 2026-05-28 | $3.71 | 2,345,400 |
| 2026-05-27 | $3.81 | 4,761,000 |
| 2026-05-26 | $3.69 | 2,541,300 |
| 2026-05-22 | $3.76 | 2,047,200 |
| 2026-05-21 | $3.76 | 1,597,200 |
| 2026-05-20 | $3.72 | 2,349,400 |
| 2026-05-19 | $3.64 | 6,754,500 |
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
đ° Latest News
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
Insider Monkey âĸ 2026-06-19T07:00:27Z
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments
Simply Wall St. âĸ 2026-06-11T17:12:46Z
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
Simply Wall St. âĸ 2026-06-05T18:22:06Z
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
Zacks âĸ 2026-06-04T17:25:00Z
Why Regeneron (REGN) Stock Is Trading Up Today
StockStory âĸ 2026-06-04T00:31:33Z
CytomX (CTMX) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-06-02T17:45:21Z
How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data And Risks
Simply Wall St. âĸ 2026-05-28T13:11:32Z
New Forecasts: Here's What Analysts Think The Future Holds For CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Simply Wall St. âĸ 2026-05-13T11:19:40Z
Earnings Beat: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St. âĸ 2026-05-11T12:49:35Z
CytomX (CTMX) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T18:04:28Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $76,201,000 | $138,103,000 | $101,214,000 | $53,163,000 |
| Operating Revenue | $76,201,000 | $138,103,000 | $101,214,000 | $53,163,000 |
| Expenses | ||||
| Total Expenses | $98,565,000 | $113,108,000 | $107,698,000 | $154,498,000 |
| Other Income Expense | $28,000 | $-38,000 | $-30,000 | $340,000 |
| Other Non Operating Income Expenses | $28,000 | $-38,000 | $-30,000 | $340,000 |
| Net Non Operating Interest Income Expense | $5,206,000 | $7,136,000 | $9,837,000 | $1,678,000 |
| Operating Expense | $98,565,000 | $113,108,000 | $107,698,000 | $154,498,000 |
| General And Administrative Expense | $29,837,000 | $29,726,000 | $30,018,000 | $42,849,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Net Interest Income | $5,206,000 | $7,136,000 | $9,837,000 | $1,678,000 |
| Interest Income | $5,206,000 | $7,136,000 | $9,837,000 | $1,678,000 |
| Normalized Income | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Net Income From Continuing And Discontinued Operation | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Total Operating Income As Reported | $-22,364,000 | $24,995,000 | $-6,484,000 | $-101,335,000 |
| Net Income Common Stockholders | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Net Income | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Net Income Including Noncontrolling Interests | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Net Income Continuous Operations | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Pretax Income | $-17,130,000 | $32,093,000 | $3,323,000 | $-99,317,000 |
| Interest Income Non Operating | $5,206,000 | $7,136,000 | $9,837,000 | $1,678,000 |
| Operating Income | $-22,364,000 | $24,995,000 | $-6,484,000 | $-101,335,000 |
| Per Share | ||||
| Diluted EPS | $-0.15 | $0.38 | $-0.01 | $-1.51 |
| Basic EPS | $-0.15 | $0.38 | $-0.01 | $-1.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-20,988,000 | $26,763,000 | $-4,309,000 | $-98,892,000 |
| Reconciled Depreciation | $1,376,000 | $1,768,000 | $2,175,000 | $2,443,000 |
| EBITDA (Bullshit earnings) | $-20,988,000 | $26,763,000 | $-4,309,000 | $-98,892,000 |
| EBIT | $-22,364,000 | $24,995,000 | $-6,484,000 | $-101,335,000 |
| Diluted Average Shares | $137,935,873 | $84,745,116 | $73,808,237 | $65,739,844 |
| Basic Average Shares | $137,935,873 | $84,439,303 | $73,808,237 | $65,739,844 |
| Diluted NI Availto Com Stockholders | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Tax Provision | $238,000 | $224,000 | $3,892,000 | $0 |
| Research And Development | $68,728,000 | $83,382,000 | $77,680,000 | $111,649,000 |
| Selling General And Administration | $29,837,000 | $29,726,000 | $30,018,000 | $42,849,000 |
| Other Gand A | $29,837,000 | $29,726,000 | $30,018,000 | $42,849,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $97,621,000 | $-1,988,000 | $-49,125,000 | $-87,575,000 |
| Total Assets | $151,566,000 | $120,533,000 | $201,792,000 | $260,891,000 |
| Total Non Current Assets | $7,645,000 | $13,228,000 | $18,856,000 | $23,789,000 |
| Other Non Current Assets | $1,558,000 | $1,093,000 | $1,000,000 | $944,000 |
| Goodwill And Other Intangible Assets | $1,387,000 | $1,532,000 | $1,678,000 | $1,824,000 |
| Other Intangible Assets | $438,000 | $583,000 | $729,000 | $875,000 |
| Current Assets | $143,921,000 | $107,305,000 | $182,936,000 | $237,102,000 |
| Other Current Assets | $4,856,000 | $3,579,000 | $4,995,000 | $7,466,000 |
| Receivables | $2,013,000 | $3,103,000 | $3,432,000 | $35,986,000 |
| Accounts Receivable | $2,013,000 | $3,103,000 | $3,432,000 | $35,986,000 |
| Cash Cash Equivalents And Short Term Investments | $137,052,000 | $100,623,000 | $174,509,000 | $193,650,000 |
| Cash And Cash Equivalents | $12,667,000 | $38,052,000 | $17,171,000 | $193,650,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $4,240,000 | $9,385,000 | $13,974,000 | $18,057,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $4,240,000 | $9,385,000 | $13,975,000 |
| Current Debt And Capital Lease Obligation | $4,240,000 | $5,145,000 | $4,589,000 | $4,082,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $52,558,000 | $120,989,000 | $249,239,000 | $346,642,000 |
| Total Non Current Liabilities Net Minority Interest | $5,943,000 | $35,217,000 | $93,326,000 | $194,034,000 |
| Other Non Current Liabilities | $4,353,000 | $4,115,000 | $3,893,000 | - |
| Non Current Deferred Liabilities | $1,590,000 | $26,862,000 | $80,048,000 | $180,059,000 |
| Current Liabilities | $46,615,000 | $85,772,000 | $155,913,000 | $152,608,000 |
| Current Deferred Liabilities | $26,877,000 | $67,201,000 | $132,267,000 | $121,267,000 |
| Payables And Accrued Expenses | $15,498,000 | $13,426,000 | $19,057,000 | $27,259,000 |
| Payables | $1,301,000 | $1,088,000 | $1,458,000 | $2,809,000 |
| Accounts Payable | $1,301,000 | $1,088,000 | $1,458,000 | $2,809,000 |
| Equity | ||||
| Common Stock Equity | $99,008,000 | $-456,000 | $-47,447,000 | $-85,751,000 |
| Total Equity Gross Minority Interest | $99,008,000 | $-456,000 | $-47,447,000 | $-85,751,000 |
| Stockholders Equity | $99,008,000 | $-456,000 | $-47,447,000 | $-85,751,000 |
| Gains Losses Not Affecting Retained Earnings | $111,000 | $27,000 | $95,000 | $10,000 |
| Other Equity Adjustments | $111,000 | $27,000 | $95,000 | $10,000 |
| Retained Earnings | $-711,949,000 | $-691,579,000 | $-723,448,000 | $-722,879,000 |
| Other | ||||
| Ordinary Shares Number | $170,186,365 | $80,099,889 | $67,310,838 | $66,228,046 |
| Share Issued | $170,186,365 | $80,099,889 | $67,310,838 | $66,228,046 |
| Tangible Book Value | $97,621,000 | $-1,988,000 | $-49,125,000 | $-87,575,000 |
| Invested Capital | $99,008,000 | $-456,000 | $-47,447,000 | $-85,751,000 |
| Working Capital | $97,306,000 | $21,533,000 | $27,023,000 | $84,494,000 |
| Capital Lease Obligations | $4,240,000 | $9,385,000 | $13,974,000 | $18,057,000 |
| Total Capitalization | $99,008,000 | $-456,000 | $-47,447,000 | $-85,751,000 |
| Additional Paid In Capital | $810,844,000 | $691,095,000 | $675,905,000 | $637,117,000 |
| Capital Stock | $2,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $2,000 | $1,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,590,000 | $26,862,000 | $80,048,000 | $180,059,000 |
| Long Term Capital Lease Obligation | $0 | $4,240,000 | $9,385,000 | $13,975,000 |
| Current Deferred Revenue | $26,877,000 | $67,201,000 | $132,267,000 | $121,267,000 |
| Current Capital Lease Obligation | $4,240,000 | $5,145,000 | $4,589,000 | $4,082,000 |
| Current Accrued Expenses | $14,197,000 | $12,338,000 | $17,599,000 | $24,450,000 |
| Goodwill | $949,000 | $949,000 | $949,000 | $949,000 |
| Net PPE | $4,700,000 | $10,603,000 | $16,178,000 | $21,021,000 |
| Accumulated Depreciation | $-16,920,000 | $-16,231,000 | $-14,688,000 | $-14,373,000 |
| Gross PPE | $21,620,000 | $26,834,000 | $30,866,000 | $35,394,000 |
| Leases | $1,604,000 | $2,005,000 | $1,983,000 | $1,742,000 |
| Construction In Progress | $0 | $0 | $368,000 | $705,000 |
| Other Properties | $3,396,000 | $8,136,000 | $12,220,000 | $15,949,000 |
| Machinery Furniture Equipment | $16,620,000 | $16,693,000 | $16,295,000 | $16,998,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $124,385,000 | $62,571,000 | $157,338,000 | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-75,807,000 | $-86,541,000 | $-56,875,000 | $-112,528,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-75,587,000 | $-86,231,000 | $-56,035,000 | $-110,788,000 |
| Cash Flow From Continuing Operating Activities | $-75,587,000 | $-86,231,000 | $-56,035,000 | $-110,788,000 |
| Investing Activities | ||||
| Capital Expenditure | $-220,000 | $-310,000 | $-840,000 | $-1,740,000 |
| Investing Cash Flow | $-59,744,000 | $99,700,000 | $-150,674,000 | $98,260,000 |
| Cash Flow From Continuing Investing Activities | $-59,744,000 | $99,700,000 | $-150,674,000 | $98,260,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $109,635,000 | $6,909,000 | - | $0 |
| Financing Cash Flow | $110,446,000 | $7,522,000 | $30,230,000 | $648,000 |
| Cash Flow From Continuing Financing Activities | $110,446,000 | $7,522,000 | $30,230,000 | $648,000 |
| Net Common Stock Issuance | $109,635,000 | $6,909,000 | - | $0 |
| Common Stock Issuance | $109,635,000 | $6,909,000 | - | $0 |
| Other | ||||
| End Cash Position | $14,194,000 | $39,079,000 | $18,088,000 | $194,567,000 |
| Beginning Cash Position | $39,079,000 | $18,088,000 | $194,567,000 | $206,447,000 |
| Changes In Cash | $-24,885,000 | $20,991,000 | $-176,479,000 | $-11,880,000 |
| Proceeds From Stock Option Exercised | $811,000 | $613,000 | $30,230,000 | $648,000 |
| Net Investment Purchase And Sale | $-59,524,000 | $100,010,000 | $-149,834,000 | $100,000,000 |
| Sale Of Investment | $133,000,000 | $255,500,000 | $275,000,000 | $100,000,000 |
| Purchase Of Investment | $-192,524,000 | $-155,490,000 | $-424,834,000 | $0 |
| Net PPE Purchase And Sale | $-220,000 | $-310,000 | $-840,000 | $-1,740,000 |
| Purchase Of PPE | $-220,000 | $-310,000 | $-840,000 | $-1,740,000 |
| Change In Working Capital | $-68,576,000 | $-126,415,000 | $-62,509,000 | $-30,654,000 |
| Change In Other Working Capital | $-65,596,000 | $-118,252,000 | $-89,011,000 | $16,565,000 |
| Change In Payables And Accrued Expense | $-2,828,000 | $-9,925,000 | $-8,467,000 | $-9,716,000 |
| Change In Accrued Expense | $-3,049,000 | $-9,628,000 | $-7,041,000 | $-9,784,000 |
| Change In Payable | $221,000 | $-297,000 | $-1,426,000 | $68,000 |
| Change In Account Payable | $221,000 | $-297,000 | $-1,426,000 | $68,000 |
| Change In Prepaid Assets | $-1,242,000 | $1,433,000 | $2,415,000 | $-3,181,000 |
| Change In Receivables | $1,090,000 | $329,000 | $32,554,000 | $-35,196,000 |
| Changes In Account Receivables | $1,090,000 | $329,000 | $32,554,000 | $-35,196,000 |
| Other Non Cash Items | $4,483,000 | $4,084,000 | $3,729,000 | $3,413,000 |
| Stock Based Compensation | $6,302,000 | $7,668,000 | $8,558,000 | $13,125,000 |
| Asset Impairment Charge | $402,000 | $106,000 | $0 | $254,000 |
| Amortization Of Securities | $-2,206,000 | $-5,311,000 | $-7,419,000 | $-52,000 |
| Depreciation Amortization Depletion | $1,376,000 | $1,768,000 | $2,175,000 | $2,443,000 |
| Depreciation And Amortization | $1,376,000 | $1,768,000 | $2,175,000 | $2,443,000 |
| Amortization Cash Flow | $146,000 | $146,000 | $146,000 | $146,000 |
| Amortization Of Intangibles | $146,000 | $146,000 | $146,000 | $146,000 |
| Depreciation | $1,230,000 | $1,622,000 | $2,029,000 | $2,297,000 |
| Net Income From Continuing Operations | $-17,368,000 | $31,869,000 | $-569,000 | $-99,317,000 |
| Change In Other Current Assets | - | - | $-56,000 | $874,000 |
| Income Tax Paid Supplemental Data | - | - | - | - |
Fetched: 2026-06-17